Pharma document review on Amazon Bedrock needs human approval

When a regulatory team has to reconcile the same study report, protocol, label, safety signal, and quality record across several submission modules, the work does not fail because people are careless. It fails because the evidence is scattered, versions conflict, and every check has to be traceable back to the source document, not to a plausible summary.

A human-approved Amazon Bedrock architecture can narrow that work by automating extraction, comparison, evidence retrieval, and draft findings, while qualified reviewers approve every regulated conclusion or system action. It is a reference design for a problem that sits across regulatory affairs, clinical, safety, quality, biostatistics, medical writing, and legal teams.

The deployment should improve speed without promising a specific time savings. The point is to move the machine into the parts of the job where software can help and keep the final call with the reviewer.

Regulatory review is slow for reasons software does not remove

Public evidence from the FDA shows that AI used to support drug and biological product submissions is now a regulatory issue in its own right, and that credibility has to be established for the specific context of use. That pushes work into validation, evidence generation, and traceability, where generic automation projects often stall.

The other problem is the source material. Submission content arrives as PDFs, scans, spreadsheets, tables, emails, images, and prior filings, often with duplicate text, version conflicts, and weak metadata. A language model answer is not enough unless every assertion points to a document ID, section, page, version, and effective date that a reviewer can inspect.

In practice, the useful system is a controlled review workflow that can find evidence, compare versions, extract structured fields, draft a disposition, and stop short of any regulated action until a human signs off.

Amazon Bedrock Knowledge Bases are designed to handle the managed retrieval pieces that map directly to recurring review work: ingestion, chunking, embeddings, vector retrieval, and prompt augmentation. That matters because a review team spends far more time locating and reconciling evidence than composing final prose.

Amazon Bedrock Agents can coordinate multistep tasks, query knowledge bases, call enterprise APIs, and then return control to the application instead of completing a regulated action autonomously. That is the right boundary for pharma review. An agent can gather the materials, draft the comparison, and propose a conclusion, but it should not write back to a submission system, mark a review complete, or issue an externally visible response without approval.

The architecture starts with controlled evidence, not model prompts

The reference design begins with source systems that already hold regulated content: controlled document repositories, submission systems, clinical data warehouses, safety databases, quality systems, and approved external scientific sources. Documents land in immutable storage with malware scanning, file-type validation, source identifiers, version metadata, retention labels, access tags, encryption, key management, and audit logging.

From there, deterministic parsing does the first pass. Optical character recognition, table extraction, terminology normalization, and entity linking should happen before any generative step. The goal is to preserve the original file, create a tamper-evident processing record, and keep the review lineage intact as the document moves through the pipeline.

The retrieval layer then combines full-text search, vector search, metadata filters, and structured fields so the model can work from the smallest relevant evidence set. A comparison request should surface the exact protocol clause that changed, the table row that moved, the adverse event term that shifted, or the label statement that no longer matches the underlying study report.

The reasoning layer uses separate schemas for extraction, comparison, classification, and drafting. Dates, numbers, thresholds, and required fields belong in deterministic rules, while low-confidence cases and high-impact findings stay in a mandatory human queue. The reviewer should spend time on judgment instead of search.

Once the workflow produces a proposed finding, the approval layer shows the source side by side with the generated output, the evidence citations, and the document version history. Only after authorization does the final system of record receive the approved result, while the original model output remains stored separately for audit and review.

This sequence is intentionally conservative. It is built for a regulated environment where the first answer has to survive inspection by quality, regulatory affairs, safety, and sometimes an auditor or an agency.

Human approval is the control

The strongest versions of this design do not treat human review as a courtesy step at the end. They make it the mechanism that separates draft work from regulated work. The reviewer sees the proposed conclusion, the evidence trail, the model and system versions, the confidence level, and any unresolved conflict between source documents.

That also changes what gets measured. The right baseline is documents and pages per submission, reviewer hours per document, cycle time, rework, finding recurrence, escalation rate, and approval latency. Without those measures, nobody can tell whether the system is helping the queue or simply moving work into a different folder.

Evaluation has to be locked to real cases. A golden set of historical and synthetic examples should test evidence recall, unsupported-claim rate, extraction precision and recall, reviewer acceptance, edit distance, time per case, and false-negative rate. Changes to prompts, retrieval, parsers, or models should be tested against that same set before they touch production.

Bedrock Agents can also support the controlled workflow around those cases. They can break a review request into retrieval, extraction, comparison, and draft-generation steps, but read-only actions should be the default and any write-back should wait for explicit approval. That keeps the system inside the limits that the FDA’s risk-based approach expects for AI used in regulatory decision support.

Where this design fails, and what has to be true first

The main failure mode is a false sense of certainty. If the source corpus is incomplete, if version control is poor, or if the workflow cannot prove which document was used for which finding, the system can produce polished answers that are harder to challenge than a human draft. In a regulated setting, that is worse than no automation at all.

It also costs real effort to get right. Teams need access control, terminology services, workflow tools, audit logs, and write-back discipline across document repositories, safety systems, quality systems, and submission management. They need subject matter experts to label the golden set, review exceptions, and decide which findings require specialist escalation.

That is the honest tradeoff. The architecture can reduce review effort by moving humans onto higher-value decisions, but only when the company accepts that the machine is not the approver, the review corpus is governed, and the evidence trail is part of the product, not a byproduct.

For teams already trying to reconcile submission quality with smaller headcount, the decision is whether to keep adding people to a process that scales poorly or to build a governed workflow where the model drafts, the evidence is machine-retrievable, and the reviewer stays accountable for the final call. QueryNow builds the foundation enterprise AI runs on, and the agents that run on it. Talk to our team about the workflow you want to start with.

Sources

• FDA Proposes Framework to Advance Credibility of AI ..., 2025-06-01